Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

This study has been terminated.
(Limited efficacy response observed during interim analysis.)
Sponsor:
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00817362
First received: January 5, 2009
Last updated: December 7, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2011
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 6, 2012